We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Tobacco Mosaic Virus Nanoparticle Delivery System Increases Potency of Experimental Anticancer Drug

By LabMedica International staff writers
Posted on 20 Jun 2016
Print article
Image: When packaged inside tobacco mosaic virus nanoparticles, phenanthriplatin is delivered to tumors, where it was shown to be more effective in vivo than an approved platin (Photo courtesy of Case Western Reserve University).
Image: When packaged inside tobacco mosaic virus nanoparticles, phenanthriplatin is delivered to tumors, where it was shown to be more effective in vivo than an approved platin (Photo courtesy of Case Western Reserve University).
A candidate anticancer drug was found to be considerably more potent than standard treatments and this potency was further increased in a mouse model when the drug was delivered by a tobacco mosaic virus (TMV)-based transport system.

The experimental anticancer drug candidate phenanthriplatin (cis-[Pt(NH3)2Cl(phenanthridine)](NO3)), is a cationic monofunctional DNA-binding platinum(II) compound with unusual potency and cellular response profiles that was developed at the Massachusetts Institute of Technology (Cambridge, USA).

Despite being up to 40 times more potent than traditional platin agents when tested directly against cancer cells growing in culture, the compound performed no better than standard platins in mouse models. To enhance the delivery of the drug investigators at Case Western Reserve University (Cleveland, OH, USA) used tobacco mosaic virus (TMV) as a delivery system (designated PhenPt-TMV). TMV forms hollow nanotubes with a polyanionic interior surface. The investigators capitalized on this native structure to develop a one-step phenanthriplatin loading protocol.

They reported in the April 26, 2016, issue of the journal ACS Nano that phenanthriplatin was released from the carrier when subjected to the acidic environment with tumor cells. In vivo tumor delivery and efficacy were confirmed by using a mouse model of triple negative breast cancer. Tumors treated with PhenPt-TMV were four times smaller than tumors treated with free phenanthriplatin or cisplatin, owing to increased accumulation of phenanthriplatin within the tumor tissue.

"We may have found the perfect carrier for this particular drug candidate," said senior author Dr. Nicole Steinmetz, assistant professor of biomedical engineering at Case Western Reserve University. "The long, thin tobacco mosaic virus nanoparticles are naturals for delivering the drug candidate into tumors. Phenanthriplatin is about one nanometer across and, when treated with silver nitrate, has a strong positive charge. It readily enters and binds to the central lining. Inside tumors, the nanoparticles gather inside the lysosomal compartments of cancer cells, where they are, in essence, digested. The pH is much lower than in the circulating blood. The shell deteriorates and releases phenanthriplatin."

Related Links:
Massachusetts Institute of Technology
Case Western Reserve University
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.